Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer: the VOICE trial

MLA

Chihiro Kosugi, et al. Multicenter Phase II Clinical Study of the Efficiency and Safety of Capecitabine plus Intermittent Oxaliplatin with Bevacizumab as First-Line Therapy in Patients with Metastatic Colorectal Cancer: The VOICE Trial. Apr. 2021. EBSCOhost, https://doi.org/10.21203/rs.3.rs-288081/v1.

APA

Chihiro Kosugi, Keiji Koda, Tadamichi Denda, Keiichiro Ishibashi, Hideyuki Ishida, Kazuhiro Seike, Haruhito Sakata, Shinji Yanagisawa, Akinari Miyazaki, Wataru Takayama, Naoto Koike, Hiroaki Shimizu, & Hisahiro Matsubara. (2021). Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer: the VOICE trial. https://doi.org/10.21203/rs.3.rs-288081/v1

Chicago

Chihiro Kosugi, Keiji Koda, Tadamichi Denda, Keiichiro Ishibashi, Hideyuki Ishida, Kazuhiro Seike, Haruhito Sakata, et al. 2021. “Multicenter Phase II Clinical Study of the Efficiency and Safety of Capecitabine plus Intermittent Oxaliplatin with Bevacizumab as First-Line Therapy in Patients with Metastatic Colorectal Cancer: The VOICE Trial,” April. doi:10.21203/rs.3.rs-288081/v1.